Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical Relating to Two Biosimilars AVT34 and AVT87 in Asian Markets

On August 23, 2026, Alvotech and Lotus Pharmaceutical have reached a strategic licensing and commercialization agreement relating to two biosimilars, AVT34 for durvalumab and AVT87 for emicizumab, in the United States and in certain Asian framework. In the United States, the semi-exclusive arrangement enables Alvotech to commercialize the products together with Lotus, and Alvotech continues to be in charge of progress, obtaining regulatory approvals and guaranteeing supply chain resilience. The agreement may bring Alvotech up to about $150 million through upfront and milestone payments as well as from product supply revenues. 

The strategic biosimilar partnership could improve market access and the competitive landscape for high-value biologic treatments in the fields of oncology and hemophilia by promoting expansion. Lotus will have exclusive commercialization rights for AVT34 and AVT87 in eight Asian areas including the Philippines, South Korea, Taiwan, Vietnam, Singapore, Thailand, Hong Kong and Malaysia. Additionally, Alvotech's capabilities in the development and manufacturing of biosimilars with Lotus's regional commercial infrastructure broaden access to high-quality biologics.

Impact on the Biopharmaceutical Industry

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035.

According to Precedence Research, the agreement is of great strategic importance to the biopharmaceutical industry since it shows the way in which specialised biosimilar developers can link up their global manufacturing capabilities with regional knowledge of commercialisation. Alvotech will retain responsibility for development, as well as for U.S. regulatory matters and supply, while Lotus will handle commercial access in eight Asian markets. This approach permits the reduction of the operational difficulties involved in entering various markets and at the same time allows both companies to benefit from the high demand for biologic products. The agreement also reflects the growing interest in biosimilars aimed at major biologic therapies and may therefore lead to more partnerships, licensing deals and competitive launches. Since pharmaceutical companies are looking in search of scalable methods to improve market access and to bring treatment costs under control, joint efforts that combine development expertise with well-established regional distribution networks are likely to become more important in the global biopharmaceutical field.

Impact on the Cancer Immunotherapy Industry

The global cancer immunotherapy market size is valued at USD 136.39 billion in 2025 and is predicted to increase from USD 151.26 billion in 2026 to approximately USD 367.63 billion by 2035, expanding at a CAGR of 10.42% from 2026 to 2035.

According to Precedence Research, the rising number of regulatory approvals for the biosimilar AVT34 being proposed by Durvalumab and AVT87 being proposed by emicizumab is becoming strategically meaningful.  The commercial demand for immuno-oncology treatment and increased competition from biosimilars might eventually lead to more affordable treatment alternatives and broaden patient access to immunotherapies to achieve governmental approvals and market-entry requirements. 

The final market impact will be determined by regulatory approvals, reimbursement policies, patent issues, pricing policies, and physician acceptance. The partnership offers Lotus a chance to improve its oncology portfolio in a number of selected Asian markets, enabling Alvotech to obtain an extra commercialization route in the United States. Additionally, should AVT34 be successfully approved and launched, it could help make the cancer immunotherapy market more competitive and put high pressure on the pricing of existing biologic therapies.

Impact on the Hemophilia Industry

The global hemophilia market size was estimated at USD 12.50 billion in 2025 and is predicted to increase from USD 13.31billion in 2026 to approximately USD 23.46 billion by 2035, expanding at a CAGR of 6.50% from 2026 to 2035.

According to Precedence Research, the growing diagnosis rates and advanced prophylactic therapies could be significantly affected by the proposed biosimilar AVT87 from Lotus. Lotus's existing business operations in a number of Asian markets should help with meeting regulatory standards, and Alvotech brings its abilities in the development and manufacturing of biosimilars.

Greater competition from biosimilars might provide medical systems with the chance to improve affordability and could in turn lead to higher access to treatment for hemophilia. The therapies based on biologics for hemophilia necessitate both the support of physicians and patients to support effective commercialization by maintaining consistent quality, safety, efficacy, and dependable availability in the diversified infrastructure.

Expert Opinion

According to expert opinion, this agreement is strategically crucial in the United States by extending access in certain Asian markets. By integrating commercialization rights with Lotus, Alvotech would be able to secure downstream value by reducing reliance on licensing arrangements. This partnership includes two biosimilar candidates, which are vital for oncology, cancer immunotherapy, and hemophilia.

The possible $150 million in upfront and breakthrough payments offer a meaningful financial advantage by generating an extra recurring stream of income. The adoption of candidates be successfully developed and launched this collaboration established solid example of combining biosimilar manufacturing expertise with domestic commercialization abilities in diversified market.